Published in Korean J Intern Med on June 01, 2006
Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med (1991) 4.66
Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med (1991) 2.59
Ischemic hepatitis: clinical presentation and pathogenesis. Am J Med (2000) 2.40
Current concepts in the diagnosis and management of thrombotic thrombocytopenic purpura. Hematol Oncol Clin North Am (2003) 0.87
Thrombotic thrombocytopenic purpura following coronary artery bypass graft surgery: prospective observations of an emerging syndrome. J Clin Apher (1997) 0.86
Clopidogrel-induced thrombotic thrombocytopenic purpura-hemolytic uremic syndrome after coronary artery stenting. Pharmacotherapy (2004) 0.85
Postoperative thrombotic thrombocytopenic purpura following cardiovascular surgeries. Am J Hematol (1996) 0.84
Thrombotic thrombocytopenic purpura: 24 years of experience at the American University of Beirut Medical Center. J Clin Apher (2004) 0.83
[Ischemic hepatitis in patients with heart failure]. An Med Interna (2003) 0.82
Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med (2010) 6.37
Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Circulation (2013) 2.55
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation (2011) 2.40
Hybrid iFR-FFR decision-making strategy: implications for enhancing universal adoption of physiology-guided coronary revascularisation. EuroIntervention (2013) 2.15
Optimal intravascular ultrasound criteria and their accuracy for defining the functional significance of intermediate coronary stenoses of different locations. JACC Cardiovasc Interv (2011) 1.94
Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial. J Am Coll Cardiol (2011) 1.70
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J (2015) 1.68
Clinical and physiological outcomes of fractional flow reserve-guided percutaneous coronary intervention in patients with serial stenoses within one coronary artery. JACC Cardiovasc Interv (2012) 1.62
Outcomes of percutaneous coronary intervention in intermediate coronary artery disease: fractional flow reserve-guided versus intravascular ultrasound-guided. JACC Cardiovasc Interv (2010) 1.61
Variability of fractional flow reserve according to the methods of hyperemia induction. Catheter Cardiovasc Interv (2014) 1.51
Outcomes of medically treated patients with aortic intramural hematoma. Am J Med (2002) 1.48
Anatomic and functional evaluation of bifurcation lesions undergoing percutaneous coronary intervention. Circ Cardiovasc Interv (2010) 1.42
Clinical Relevance of Poststent Fractional Flow Reserve After Drug-Eluting Stent Implantation. J Invasive Cardiol (2015) 1.41
Effects of PGC-1alpha on TNF-alpha-induced MCP-1 and VCAM-1 expression and NF-kappaB activation in human aortic smooth muscle and endothelial cells. Antioxid Redox Signal (2007) 1.21
Predictors of six-month major adverse cardiac events in 30-day survivors after acute myocardial infarction (from the Korea Acute Myocardial Infarction Registry). Am J Cardiol (2009) 1.21
Outcomes after unrestricted use of everolimus-eluting and sirolimus-eluting stents in routine clinical practice: a multicenter, prospective cohort study. Circ Cardiovasc Interv (2012) 1.15
Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. Am J Cardiol (2009) 1.03
Gender differences in clinical features and in-hospital outcomes in ST-segment elevation acute myocardial infarction: from the Korean Acute Myocardial Infarction Registry (KAMIR) study. Clin Cardiol (2010) 0.97
Alpha-lipoic acid inhibits matrix metalloproteinase-9 expression by inhibiting NF-kappaB transcriptional activity. Exp Mol Med (2007) 0.97
Suboptimal use of evidence-based medical therapy in patients with acute myocardial infarction from the Korea Acute Myocardial Infarction Registry: prescription rate, predictors, and prognostic value. Am Heart J (2010) 0.96
Relationship between Chemerin Levels and Cardiometabolic Parameters and Degree of Coronary Stenosis in Korean Patients with Coronary Artery Disease. Diabetes Metab J (2011) 0.96
Incidence of hypertension in Korea: 5-year follow-up study. J Korean Med Sci (2011) 0.96
Drug-eluting stent thrombosis during perioperative period. Int Heart J (2008) 0.95
Clinical validation of the resting pressure parameters in the assessment of functionally significant coronary stenosis; results of an independent, blinded comparison with fractional flow reserve. Int J Cardiol (2013) 0.95
Melittin inhibits atherosclerosis in LPS/high-fat treated mice through atheroprotective actions. J Atheroscler Thromb (2011) 0.93
Reversible pulmonary hypertension in adolescent with left atrial myxoma. J Cardiovasc Ultrasound (2011) 0.92
Usefulness of tissue Doppler imaging-myocardial performance index in the evaluation of diastolic dysfunction and heart failure with preserved ejection fraction. Clin Cardiol (2011) 0.91
Fractional flow reserve versus angiography in left circumflex ostial intervention after left main crossover stenting. Korean Circ J (2011) 0.90
The correlation of left atrial volume index to the level of N-terminal pro-BNP in heart failure with a preserved ejection fraction. Echocardiography (2008) 0.89
Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia. Korean J Intern Med (2010) 0.89
Safety and efficacy of a novel hyperaemic agent, intracoronary nicorandil, for invasive physiological assessments in the cardiac catheterization laboratory. Eur Heart J (2013) 0.89
Cor triatriatum dexter assessed by three-dimensional echocardiography reconstruction in two adult patients. Echocardiography (2007) 0.89
Prognosis and natural history of drug-related bradycardia. Korean Circ J (2009) 0.88
Decision-making model for early diagnosis of congestive heart failure using rough set and decision tree approaches. J Biomed Inform (2012) 0.88
Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients--clilostazol for diabetic patients in drug-eluting stent (CIDES) trial. Circ J (2008) 0.88
Effect of NF-κB decoy oligodeoxynucleotide on LPS/high-fat diet-induced atherosclerosis in an animal model. Basic Clin Pharmacol Toxicol (2010) 0.88
Relationship between early diastolic strain rate imaging and left ventricular geometric patterns in hypertensive patients. Heart Vessels (2008) 0.88
Paclitaxel- versus sirolimus-eluting stents for treatment of ST-segment elevation myocardial infarction: with analyses for diabetic and nondiabetic subpopulation. JACC Cardiovasc Interv (2010) 0.88
TNF-α polymorphisms and coronary artery disease: association study in the Korean population. Cytokine (2013) 0.88
Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III. Am Heart J (2007) 0.87
Incidence and clinical significance of myocardial bridging with ECG-gated 16-row MDCT coronary angiography. Int J Cardiovasc Imaging (2007) 0.87
Ovarian tumor-associated carcinoid heart disease presenting as severe tricuspid regurgitation. J Cardiovasc Ultrasound (2011) 0.87
Everolimus-eluting stent implantation for unprotected left main coronary artery stenosis. The PRECOMBAT-2 (Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease) study. JACC Cardiovasc Interv (2012) 0.87
Comparison of early strut coverage between zotarolimus- and everolimus-eluting stents using optical coherence tomography. Am J Cardiol (2012) 0.86
Comparison of 5-year clinical outcomes between sirolimus-versus paclitaxel-eluting stent: Korean multicenter network analysis of 9000-patient cohort. Circ Cardiovasc Interv (2012) 0.86
Evaluation of myocardial bridge with multidetector computed tomography. Circ J (2009) 0.86
Analysis of proteome and transcriptome of tumor necrosis factor alpha stimulated vascular smooth muscle cells with or without alpha lipoic acid. Proteomics (2004) 0.85
Impact of home-based exercise training with wireless monitoring on patients with acute coronary syndrome undergoing percutaneous coronary intervention. J Korean Med Sci (2013) 0.84
Two-dimensional strain or strain rate findings in mild to moderate diastolic dysfunction with preserved ejection fraction. Heart Vessels (2010) 0.84
High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting. Int J Cardiol (2012) 0.84
Uric Acid as prognostic marker in advanced nonischemic dilated cardiomyopathy: comparison with N-terminal pro B-type natriuretic peptide level. Congest Heart Fail (2010) 0.83
Association of promoter region single nucleotide polymorphisms at positions -819C/T and -592C/A of interleukin 10 gene with ischemic heart disease. Inflamm Res (2012) 0.82
The coffee diterpene kahweol sensitizes TRAIL-induced apoptosis in renal carcinoma Caki cells through down-regulation of Bcl-2 and c-FLIP. Chem Biol Interact (2010) 0.82
ComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT). Am Heart J (2012) 0.81
Alpha-lipoic acid attenuates atherosclerotic lesions and inhibits proliferation of vascular smooth muscle cells through targeting of the Ras/MEK/ERK signaling pathway. Mol Biol Rep (2012) 0.81